109.40
-0.27%
Close of 9 Nov 2026, in ILA
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Israel Canada Hotels
Its shares trade on Tel Aviv under the ticker ICHO.TA. It has been listed since 13 May 2007. In the fiscal year to 31 December 2024, it reported revenue of ILS 306,000 and net income of ILS 22.1m. At that date it held total assets of ILS 104.3m and shareholders' equity of ILS 101.5m.
DNA Group (T.R.)Ltd. engages in investing in biomedical companies and real estate. The firm's areas of activity include: the evaluation of bone density by measuring the velocity of the propagation of sound waves across the bone, using Bimmed, as well as the development of oral delivery of drugs, through its subsidiary, Entera Bio Ltd. Entera Bio Ltd focuses on the development of oral delivery of large molecules to address unmet medical needs. Entera Bio Ltd holds a patent, combining the following technologies: a synthetic molecule absorption enhancer, facilitating the absorption of large molecules and a proprietary formulation to prevent molecule degradation. Entera Bio Ltd’s proprietary oral delivery platform can be applied to a range of large molecules and biologicals. Entera Bio Ltd’s drugs are designated for the following medical conditions: Hypoparathyroidism and Osteoporosis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Information Technology
- Industry
- Electronic Equipment, Instruments & Components
- Listed since
- 13 May 2007
Leadership
Pay as last reported
- Mr. Zeev BronfeldChairman of the Board, since 2009
- Mr. Yonatan MalcaChief Executive Officer, Director, since 2009
- Mr. Tony KleinVice President - Finance
- Mr. Daniel SpiraInternal Auditor
- Mr. Ronen MidbariExternal Director
- Ms. Rachel ShavitExternal Director
- Mr. Eran GorenIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- DNA Group invests in biomedical companies and real estate in Israel.
- Entera Bio Ltd develops oral drug delivery for large molecules with a proprietary platform.
- Bimmed technology measures bone density using sound wave propagation across bones.
Weaknesses
- The company focuses on specific medical conditions like Hypoparathyroidism and Osteoporosis.
- Entera Bio Ltd's drugs target only two medical conditions currently.
- The firm operates in a highly regulated biomedical sector with long development cycles.
Opportunities
- Expanding oral drug delivery applications to other large molecules and biologicals.
- Increasing market share in the Israeli biomedical sector with Bimmed technology.
- Developing new partnerships for Entera Bio Ltd's drug delivery platform.
Threats
- Regulatory challenges in the biomedical industry could delay product approvals.
- Competition from other drug delivery technologies in the global market.
- Economic downturns affecting investment in biomedical research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.